Debt-to-EBITDA measures a company's ability to pay off its debt.
HilleVax's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2021 was $158.31 Mil. HilleVax's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2021 was $0.15 Mil. HilleVax's annualized EBITDA for the quarter that ended in Dec. 2021 was $-99.56 Mil.
HilleVax's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2021 was -1.59.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for HilleVax's Debt-to-EBITDA or its related term are showing as below:
HLVX'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.59 Med: -1.53 Max: -1.46
Current: -1.59
During the past 2 years, the highest Debt-to-EBITDA Ratio of HilleVax was -1.46. The lowest was -1.59. And the median was -1.53.
HLVX's Debt-to-EBITDA is ranked worse than 100% of 301
companies
in the Biotechnology industry
Industry Median: 0.91
vs HLVX: -1.59
HilleVax Debt-to-EBITDA Historical Data
The historical data trend for HilleVax's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
HilleVax Annual Data
Trend
Dec20
Dec21
Debt-to-EBITDA
-1.46
-1.59
HilleVax Semi-Annual Data
Dec20
Dec21
Debt-to-EBITDA
-1.46
-1.59
Competitive Comparison
For the Biotechnology subindustry, HilleVax's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HilleVax Debt-to-EBITDA Distribution
For the Biotechnology industry and Healthcare sector, HilleVax's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where HilleVax's Debt-to-EBITDA falls into.
HilleVax Debt-to-EBITDA Calculation
Debt-to-EBITDA measures a company's ability to pay off its debt.
HilleVax's Debt-to-EBITDA for the fiscal year that ended in Dec. 2021 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is one times the quarterly (Dec. 2021) EBITDA data.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
HilleVax Debt-to-EBITDA Related Terms
Thank you for viewing the detailed overview of HilleVax's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.61(5.05%) Volume: 19,569 4:00PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:HLVX has been successfully added to your 
